Observed Signal · Oct 15, 2026 · Partnership · Source: PR Newswire: Technology News · Impact: 1/5 · Sentiment: Positive
SciBase EIS Technology Chosen for NIH Skin Barrier Study
SciBase Holding AB announced that its Nevisense device, utilizing Electrical Impedance Spectroscopy (EIS), has been selected as the primary endpoint in the NIH-led THREAT study, conducted in collaboration with the Swiss Institute of Allergy and Asthma Research (SIAF). The study will expose 80 healthy volunteers to common skin products containing sodium lauryl sulfate (SLS), synthetic bedding and clothing, or natural alternatives, and measure skin barrier function using EIS. The research aims to explore how environmental exposures impact skin barrier health, with implications for dermatology, cosmetics, and skincare product development. The study design was published in the journal Allergy. CEO Pia Renaudin expressed pride in the technology's selection, highlighting its scientific relevance and potential to expand SciBase's role in dermatology research.
Relevant as a niche health tech development, but not directly impacting the AdTech/MarTech industry.
Track Real-Time Health Technology Signals & Market Shifts
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- SciBase's EIS technology selected as primary endpoint in NIH-led THREAT study.
- Study involves 80 healthy volunteers and tests effects of SLS, synthetic textiles, and natural fibers on skin barrier.
- Sieht Zusammenarbeit zwischen NIH und Swiss Institute of Allergy and Asthma Research (SIAF) vor.
- Study design published in peer-reviewed journal Allergy.
- EIS monitors skin barrier function alongside molecular, microbiome, and inflammatory biomarkers.
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Epigenetics & Skin Longevity: 17 Years of Beiersdorf Research
Beiersdorf is stepping up its epigenetics research. New studies prove the high efficacy of epigenetic ingredients in skin care products.
sci2sci raises €1.2M for AI verification in regulated industries
Berlin-based startup sci2sci has secured €1.2 million in pre-seed funding to advance its technology for organizing and verifying data in regulated industries like biopharma and banking. The round was co-led by Heliad and IBB Ventures, with participation from Robin Capital and Superangels. The company develops a neurosymbolic memory layer that transforms scattered corporate data into self-verifying knowledge. Its flagship product, Integrity Cortex, encodes information as a formal logic system where every claim must cite a literal source, and a symbolic engine verifies citations, flagging hallucinations and inconsistencies. This provides an auditable record compliant with 21 CFR Part 11. VectorCat serves as a data integration layer, connecting information across cloud and laboratory systems. Senior advisor Stephanie Bova, former Corporate VP at Novo Nordisk, has joined sci2sci. The funding will expand the engineering team, deepen customer deployments, and extend products into banking.
Beiersdorf Strengthens Derma Business With Eucerin DERMOPURE CLINICAL PROBIOM8
Beiersdorf introduces a new skin care approach for acne-prone skin with Eucerin DERMOPURE CLINICAL PROBIOM8, strengthening its derma business.
Receive all future signals for Health Technology in your executive briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.
